Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

NCT06577090 · Active, not recruiting

Last updated 2026-05-28

This clinical trial is testing the effects of a medication called QW Nimacimab, alone and combined with Semaglutide, on body weight in adults with obesity.

Status Active, not recruiting Ongoing, but no longer enrolling new participants.

Phase Phase 2 Tests whether it works and watches safety in a moderate group.

Type Interventional (clinical trial)

Design Randomized, quadruple-blind treatment study

Participants 136 people

Who can join Ages 18–65 · all sexes

Timeline Started 2024-08 · est. completion 2027-02

Where 16 sites · United States

What this study is testing ClinicalTrials.gov NCT06577090 ↗

Description as written by the study sponsor.

This is a proof-of-concept study to assess the safety and efficacy of Nimacimab Injection compared to an active and placebo injection control.

Treatments tested

Nimacimab injection Biologic

Nimacimab injection 200 mg
Nimacimab placebo injection Biologic

matching nimacimab placebo injection
semaglutide injection Combination Product

semaglutide injection 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, 2.4 mg + nimacimab 200 mg
Nimacimab 300 mg injection Biologic

Nimacimab injection 300 mg

Main thing measured	Percent change in body weight (main study)
Sponsor	Skye Bioscience, Inc.
Conditions studied	Obesity
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06577090 ↗